- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 515/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
Patent holdings for IPC class C07D 515/22
Total number of patents in this class: 163
10-year publication summary
|
3
|
5
|
5
|
9
|
11
|
23
|
19
|
24
|
18
|
8
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Janssen Pharmaceutica N.V. | 3407 |
22 |
| Pharma Mar, S.A. | 214 |
17 |
| Zeno Management, Inc. | 21 |
8 |
| Vertex Pharmaceuticals Incorporated | 1595 |
7 |
| AstraZeneca AB | 2924 |
6 |
| NATCO Pharma Limited | 207 |
5 |
| The Regents of the University of Michigan | 4675 |
4 |
| Abbvie Inc. | 1803 |
4 |
| AbbVie Deutschland GmbH & Co. KG | 263 |
4 |
| Genzyme Corporation | 1242 |
4 |
| Jiangsu Hengrui Medicine Co., Ltd. | 706 |
4 |
| Inflazome Limited | 85 |
4 |
| Ascentage Pharma (Suzhou) Co., Ltd. | 175 |
4 |
| Ascentage Pharma Group Corp Limited | 124 |
4 |
| F. Hoffmann-La Roche AG | 7932 |
3 |
| Gilead Sciences, Inc. | 2032 |
3 |
| Polyphor AG | 87 |
3 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 635 |
3 |
| Hoffmann-La Roche Inc. | 3400 |
2 |
| Lawrence Livermore National Security, LLC | 1929 |
2 |
| Other owners | 50 |